Risedronate once monthly: A potential new regimen for the treatment of postmenopausal osteoporosis

Clinical Interventions in Aging

Volumn 3, Issue 2, 2008, Pages 227-232

  Moro Álvarez, María J ^a   Díaz Curiel, Manuel ^b  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Bisphosphonates; Bone mineral density; Fracture; Osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

ARTHRALGIA; BACKACHE; BONE DENSITY; BONE DISEASE; BONE NECROSIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG PREFERENCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; INFLUENZA; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOLYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; UPPER ABDOMINAL PAIN; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE;

EID: 47849105372     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Actonel label. 2007. URL: http://wwww.fda.gov/cder/foi/label/2007/ 020835s0251bl.pdf
2. Baroutsou B, Babiolakis D, Stamatiadou A, et al. 2004. Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women. EULAR 2004 [AbstractSAT0240].
3. Brown JP, Kendler DL, McClung MR et al. 2002. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int, 71:103-111.
4. Caro JJ, Ishak KJ, Huybrechts KF, et al. 2004. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int, 15:1003-8.
5. Chesnut CH, Skag A, Christiansen C, et al. 2004. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res, 19:1241-9.
6. Chrischilles EA, Butler CD, Davis CS, et al. 1991. A model of lifetime osteoporosis impact. Arch Intern Med, 151:2026-32.
7. Cramer JA, Gold DT, Silverman SL, et al. 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int, 18:1023-31.
8. Cramer JA, Amonkar M, Hebborn A, et al. 2004. Assessing the relationship between bisphosphonate dosing regimen and treatment adherence among post-menopausal osteoporotic women. Arthritis Rheum, 15:S677.
9. Cranney A, Tugwell P, Adachi J, et al. 2002. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev, 23:517-23.
10. Delmas PD, Recker RR, Chesnut CH III, et al. 2004. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study, Osteoporos Int, 15:792-8.
11. Delmas PD, Benhamou CL, Man Z, et al. 2007. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int, doi: 10.1007/s00198-007-0531-9.
12. Delmas PD, McClung MR, Zanchetta JR, et al. 2008. Efficacy and safety of risedronate 150 mg once month in the treatment of postmenopausal osteoprosis. Bone, 42:36-42.
13. Eastell R, Garnero P, Vrijens B, et al. 2003. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int, 72:408 [Abstract P-297].
14. Emkey R. 2004. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med, 6:6.
15. Ettinger M, Gallagher R, Amonkar M, et al. 2004. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum, 15:S1325.
16. Finigan J, Bainbridge PR, Eastell R. 2001. Adherence to osteoporosis therapies. Osteoporos Int, 12:S48-9 [Abstract P110].
17. Gold DT, Safi W, Trinh H. 2006. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin, 22:2383-91.
18. Harris ST, Watts NB, Genant HK, et al. 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 282:1344-52.
19. Harris ST, Watts NB, Li Z, et al. 2004. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin, 20:757-64. Erratum in: Curr Med Res Opin, 20:1690.
20. Keen R, Jodar E, Iolascon G, et al. 2006. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin, 22:2375-81.
21. Kendler D, Kung AW, Fuleihan Gel-H, et al. 2004. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas, 48:243-51.
22. Lekkerkerker F, Kanis JA, Alsayed N, et al. 2007. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int, 18:1311-7.
23. Lombas C, Hakim C, Zanchetta JR. 2001. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res, 15:S529 [Abstract M406].
24. McClung MR, Geusens P, Miller PD, et al. 2001. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med, 344:333-40.
25. McCLung MR, Benhamou CL, Man Z, et al. 2007. The efficacy and tolerability of a monthly dosing regimen of 75 mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis-1 year stdy results. Osteoporos Int, 18:S217-8.
26. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. 2004. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas, 48:271-87.
27. Mellstrom DD, Sörensen OH, Goemaere S, et al. 2004. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calci Tissue Int, 75:462-68.
28. Mersfelder T, Armitstead JA, Ivey MF, et al. 1999. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag, 18:50-8.
29. Miller PD, McClung MR, Macovei L et al. 2005. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res, 20:1315-22.
30. North American Menopause Society. 2006. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause, 13:340-67.
31. Recker RR, Gallagher R, Amonkar M, et al. 2004. Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. J Bone Miner Res, 19(Suppl 1):S172 [Abstract SA407].
32. Reginster J, Minne HW, Sorensen OH, et al. 2000. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int, 11:83-91.
33. Reginster JY, Burlet N. 2006. Osteoporosis: a still increasing prevalence. Bone, 38(Suppl 1):S4-S9.
34. Sebaldt R, Shane L, Pham B, et al. 2004. Longer-term effectiveness outcomes of non-compliance and nonpersistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int, 15(Suppl 1):S107 [Abstract P391SA].
35. Segal E, Tamir A, Ish-Shalom S. 2003. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J, 5:859-62.
36. Simon JA, Lewiecki EM, Smith ME, et al. 2002. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a muticenter, randomized, openlabel, cross-over study. Clin Ther, 4:1871-86.
37. Weiss TW, Gold DT, Silverman SL et al. 2006. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin, 22:949-60.
38. World Health Organization. 2003. Adherence to long-term therapies: evidence for action. http://www.who.int/chronic_conditions/en/ adherence_report.pdf.
39. Yood RA, Emani S, Reed JI, et al. 2003. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int, 14:965-8.